| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5456846495c5fa8a02f5eaae9faae290 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2020-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdb0529b116d7ba67ce4fad767edefd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_157dec77be07ff07ce3e477259bae5e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cad18e2a506e33f6077f4125d2e2a29f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0653b03d51063fc5de9599381e0b91a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94911418a8d7b93efdef5f79dff88a22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1aec36963a1670e1376f2e6916767a0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41d1f72f3c2231beba227f9a9c8dfaa1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b384054469db0adeae1f5348746dc26d |
| publicationDate |
2022-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022096595-A1 |
| titleOfInvention |
Anti-atopic dermatitis protein |
| abstract |
Provided is an anti-atopic dermatitis protein. A corresponding pharmaceutical composition contains a pharmaceutically acceptable carrier and the anti-atopic dermatitis protein. The anti-atopic dermatitis protein is one or more proteins selected from the group consisting of Helicobacter pylori -neutrophil-activating protein (HP-NAP) and recombinant maltose-binding protein fused to neutrophil-activating protein (rMBP-NAP). HP-NAP and rMBP-NAP can effectively treat AD in an oxazolone-induced AD model, providing brand-new drugs for the treatment of AD. |
| priorityDate |
2019-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |